In June and July 2024, 19 imported cases of Oropouche virus (OROV) disease were reported for the first time in EU countries: Spain (12), Italy (5), and Germany (2), eighteen of the cases had a travel history to Cuba and one to Brazil.
The principal vector of OROV (Culicoides paraensis midge) is widely distributed across the Americas, but absent in Europe. To date, there has been a lack of evidence as to whether European midges or mosquitoes could transmit the virus. To date, no secondary transmission has ever been reported. Therefore, the risk of locally acquired OROV disease in the EU/EEA is low.
According to ECDC, the likelihood of infection for travellers to, or residing in epidemic areas in South and Central America is currently assessed as moderate. Further imported cases to Europe are likely.
Prevention: Optimal mosquito protection 24/7 (also against other mosquito-borne diseases such as dengue, Zika, Chikungunya and malaria).
Given its clinical presentation, Oropouche fever should be included in the clinical differential diagnosis for other common vector-borne diseases in the region of the Americas (e.g., malaria, dengue, chikungunya, Zika, yellow fever.
The occurrence of vertical transmission of OROV adds a new dimension to the pathogenicity of the virus. The extent of possible foetal malformations or death in the context of an OROV outbreak situation is currently still unclear and is being investigated. Until further data is available, Pregnant women and women planning to be pregnant should be provided with comprehensive information during pre-travel consultation on the OROV outbreak and the potential of miscarriage, fetal malformation or death. The current outbreaks occur in regions where Zika virus is also endemic, and travel advice for pregnant women related to ZIKV can also adequately address the potential risk associated with Oropouche virus disease; for detailed ECTM recommendations on Zika prevention, see LINK.
0
